Cargando…
The role of mutations associated with familial neurodegenerative disorders on blood–brain barrier function in an iPSC model
BACKGROUND: Blood–brain barrier dysfunction is associated with many late-stage neurodegenerative diseases. An emerging question is whether the mutations associated with neurodegenerative diseases can independently lead to blood–brain barrier (BBB) dysfunction. Studies from patient-derived induced pl...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628493/ https://www.ncbi.nlm.nih.gov/pubmed/31303172 http://dx.doi.org/10.1186/s12987-019-0139-4 |
_version_ | 1783434972976119808 |
---|---|
author | Katt, Moriah E. Mayo, Lakyn N. Ellis, Shannon E. Mahairaki, Vasiliki Rothstein, Jeffrey D. Cheng, Linzhao Searson, Peter C. |
author_facet | Katt, Moriah E. Mayo, Lakyn N. Ellis, Shannon E. Mahairaki, Vasiliki Rothstein, Jeffrey D. Cheng, Linzhao Searson, Peter C. |
author_sort | Katt, Moriah E. |
collection | PubMed |
description | BACKGROUND: Blood–brain barrier dysfunction is associated with many late-stage neurodegenerative diseases. An emerging question is whether the mutations associated with neurodegenerative diseases can independently lead to blood–brain barrier (BBB) dysfunction. Studies from patient-derived induced pluripotent stem cells suggest that mutations associated with neurodegenerative disease are non-cell autonomous, resulting in gain of toxic function in derived neurons and astrocytes. Here we assess whether selected mutations associated with neurodegenerative diseases can contribute to impairment of the blood–brain barrier. METHODS: We assessed barrier function of confluent monolayers of human brain microvascular endothelial cells (hBMECs) derived from induced pluripotent stem cells (iPSC) from three healthy individuals and eight individuals with neurodegenerative disease. We systematically assessed protein and gene expression of BBB biomarkers, transendothelial resistance (TEER), permeability of Lucifer yellow, permeability of d-glucose, permeability of rhodamine 123, the efflux ratio of rhodamine 123, and P-gp inhibition using Tariquidar for confluent monolayers of human brain microvascular endothelial cell (hBMECs). RESULTS: We provide evidence supporting the hypothesis that mutations associated with neurodegenerative disease can independently cause BBB dysfunction. These functional changes are not catastrophic since barrier breakdown would result in BBB impairment during development. Synergistic interactions between non-cell autonomous cerebrovascular dysfunction and the effects of gain-of-toxic function in neurons (e.g. toxic oligomers) are likely to increase disease burden through a positive feedback mechanism. CONCLUSIONS: These results suggest that the accumulation of defects in brain microvascular endothelial cells may ultimately lead to impairment of the BBB. Small changes in barrier function over time could lead to accumulated defects that result in positive feedback to unrelated central nervous system diseases. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12987-019-0139-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6628493 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-66284932019-07-23 The role of mutations associated with familial neurodegenerative disorders on blood–brain barrier function in an iPSC model Katt, Moriah E. Mayo, Lakyn N. Ellis, Shannon E. Mahairaki, Vasiliki Rothstein, Jeffrey D. Cheng, Linzhao Searson, Peter C. Fluids Barriers CNS Research BACKGROUND: Blood–brain barrier dysfunction is associated with many late-stage neurodegenerative diseases. An emerging question is whether the mutations associated with neurodegenerative diseases can independently lead to blood–brain barrier (BBB) dysfunction. Studies from patient-derived induced pluripotent stem cells suggest that mutations associated with neurodegenerative disease are non-cell autonomous, resulting in gain of toxic function in derived neurons and astrocytes. Here we assess whether selected mutations associated with neurodegenerative diseases can contribute to impairment of the blood–brain barrier. METHODS: We assessed barrier function of confluent monolayers of human brain microvascular endothelial cells (hBMECs) derived from induced pluripotent stem cells (iPSC) from three healthy individuals and eight individuals with neurodegenerative disease. We systematically assessed protein and gene expression of BBB biomarkers, transendothelial resistance (TEER), permeability of Lucifer yellow, permeability of d-glucose, permeability of rhodamine 123, the efflux ratio of rhodamine 123, and P-gp inhibition using Tariquidar for confluent monolayers of human brain microvascular endothelial cell (hBMECs). RESULTS: We provide evidence supporting the hypothesis that mutations associated with neurodegenerative disease can independently cause BBB dysfunction. These functional changes are not catastrophic since barrier breakdown would result in BBB impairment during development. Synergistic interactions between non-cell autonomous cerebrovascular dysfunction and the effects of gain-of-toxic function in neurons (e.g. toxic oligomers) are likely to increase disease burden through a positive feedback mechanism. CONCLUSIONS: These results suggest that the accumulation of defects in brain microvascular endothelial cells may ultimately lead to impairment of the BBB. Small changes in barrier function over time could lead to accumulated defects that result in positive feedback to unrelated central nervous system diseases. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12987-019-0139-4) contains supplementary material, which is available to authorized users. BioMed Central 2019-07-15 /pmc/articles/PMC6628493/ /pubmed/31303172 http://dx.doi.org/10.1186/s12987-019-0139-4 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Katt, Moriah E. Mayo, Lakyn N. Ellis, Shannon E. Mahairaki, Vasiliki Rothstein, Jeffrey D. Cheng, Linzhao Searson, Peter C. The role of mutations associated with familial neurodegenerative disorders on blood–brain barrier function in an iPSC model |
title | The role of mutations associated with familial neurodegenerative disorders on blood–brain barrier function in an iPSC model |
title_full | The role of mutations associated with familial neurodegenerative disorders on blood–brain barrier function in an iPSC model |
title_fullStr | The role of mutations associated with familial neurodegenerative disorders on blood–brain barrier function in an iPSC model |
title_full_unstemmed | The role of mutations associated with familial neurodegenerative disorders on blood–brain barrier function in an iPSC model |
title_short | The role of mutations associated with familial neurodegenerative disorders on blood–brain barrier function in an iPSC model |
title_sort | role of mutations associated with familial neurodegenerative disorders on blood–brain barrier function in an ipsc model |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628493/ https://www.ncbi.nlm.nih.gov/pubmed/31303172 http://dx.doi.org/10.1186/s12987-019-0139-4 |
work_keys_str_mv | AT kattmoriahe theroleofmutationsassociatedwithfamilialneurodegenerativedisordersonbloodbrainbarrierfunctioninanipscmodel AT mayolakynn theroleofmutationsassociatedwithfamilialneurodegenerativedisordersonbloodbrainbarrierfunctioninanipscmodel AT ellisshannone theroleofmutationsassociatedwithfamilialneurodegenerativedisordersonbloodbrainbarrierfunctioninanipscmodel AT mahairakivasiliki theroleofmutationsassociatedwithfamilialneurodegenerativedisordersonbloodbrainbarrierfunctioninanipscmodel AT rothsteinjeffreyd theroleofmutationsassociatedwithfamilialneurodegenerativedisordersonbloodbrainbarrierfunctioninanipscmodel AT chenglinzhao theroleofmutationsassociatedwithfamilialneurodegenerativedisordersonbloodbrainbarrierfunctioninanipscmodel AT searsonpeterc theroleofmutationsassociatedwithfamilialneurodegenerativedisordersonbloodbrainbarrierfunctioninanipscmodel AT kattmoriahe roleofmutationsassociatedwithfamilialneurodegenerativedisordersonbloodbrainbarrierfunctioninanipscmodel AT mayolakynn roleofmutationsassociatedwithfamilialneurodegenerativedisordersonbloodbrainbarrierfunctioninanipscmodel AT ellisshannone roleofmutationsassociatedwithfamilialneurodegenerativedisordersonbloodbrainbarrierfunctioninanipscmodel AT mahairakivasiliki roleofmutationsassociatedwithfamilialneurodegenerativedisordersonbloodbrainbarrierfunctioninanipscmodel AT rothsteinjeffreyd roleofmutationsassociatedwithfamilialneurodegenerativedisordersonbloodbrainbarrierfunctioninanipscmodel AT chenglinzhao roleofmutationsassociatedwithfamilialneurodegenerativedisordersonbloodbrainbarrierfunctioninanipscmodel AT searsonpeterc roleofmutationsassociatedwithfamilialneurodegenerativedisordersonbloodbrainbarrierfunctioninanipscmodel |